-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Emerging Prognostic Markers in Chronic Lymphocytic Leukemia and their Impact on Treatment Strategies

Program: Education Program
Session: New Approaches in Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia
Sunday, December 6, 2015, 9:30 AM-11:00 AM
Tangerine 2 (WF2), Level 2 (Orange County Convention Center)
Monday, December 7, 2015, 2:45 PM-4:15 PM
Chapin Theater (W320), Level 3 (Orange County Convention Center)

Stephan Stilgenbauer

Department of Internal Medicine III, Ulm University, Ulm, Germany

Disclosures: Stilgenbauer: AbbVie, Amgen, Boehringer-Ingelheim, Celgene, Genentech, Genzyme, Gilead, GSK, Janssen, Mundipharma, Novartis, Pharmacyclics, Roche: Consultancy , Honoraria , Research Funding . Off Label Use: specific anti-CLL therapy.

See more of: New Approaches in Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia
See more of: Education Program
<< Previous Presentation | Next Presentation